Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$1 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$-11 Mln
ROE
-3.7 %
ROCE
-- %
P/E Ratio
0.2
P/B Ratio
0.1
Industry P/E
--
EV/EBITDA
-0.5
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
3,778,520
CFO
CHF-162.11 Mln
EBITDA
CHF-175.19 Mln
Net Profit
CHF-180.48 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Altamira Therapeutics (CYTO)
| 10.2 | -68.5 | -78.1 | -95.1 | -94.2 | -81.7 | -76.9 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Altamira Therapeutics (CYTO)
| -96.4 | -86.6 | -30.7 | 61.7 | 255.3 | -22.7 | -44.8 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic... acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda. Read more
Founder, President, Chairman, CEO & MD
Dr. Thomas Meyer Ph.D.
Founder, President, Chairman, CEO & MD
Dr. Thomas Meyer Ph.D.
Headquarters
Hamilton
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Altamira Therapeutics Ltd (CYTO) is $0.13 (NASDAQ) as of 17-Jan-2025 09:30 EDT. Altamira Therapeutics Ltd (CYTO) has given a return of -94.15% in the last 3 years.
The P/E ratio of Altamira Therapeutics Ltd (CYTO) is 0.16 times as on 17-Jan-2025.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
The 52-week high and low of Altamira Therapeutics Ltd (CYTO) are Rs -- and Rs -- as of 03-Apr-2026.
Altamira Therapeutics Ltd (CYTO) has a market capitalisation of $ 1 Mln as on 17-Jan-2025. As per SEBI classification, it is a Small Cap company.
Before investing in Altamira Therapeutics Ltd (CYTO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.01
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.